Recent Updates
Recently added Catalysts

Newly Diagnosed Glioblastoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$371Muniverse median $1.20B
Allocated capital$53M$371M competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank287/299crowding rank 287

Newly Diagnosed Glioblastoma is uncontested. Agenus (AGEN) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Botensilimab in phase 2.

There is no public comparable to price it against. AGEN spreads its $371M market cap across 7 indications, so $53M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$53M of allocated capital sits in Newly Diagnosed Glioblastoma, ranking it 287th of 299 indications by the money committed to it.

Companies developing drugs for Newly Diagnosed Glioblastoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
AGENAgenusBotensilimabPhase 22$371MNo7 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Newly Diagnosed Glioblastoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Newly Diagnosed Glioblastoma has one competitor and a median of $371M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Metastatic Pancreatic Adenocarcinoma1 company · $53M · median $371MUncontestedMetastatic Urothelial Cancer1 company · $54M · median $214MUncontestedMetastatic Anal Cancer1 company · $51M · median $102MUncontestedAdenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma1 company · $64M · median $129MUncontestedPediatric Brain Tumor1 company · $41M · median $124MUncontestedAggressive B-Cell Non-Hodgkin's Lymphoma1 company · $34M · median $168MUncontestedFollicular Lymphoma1 company · $34M · median $168MUncontestedLow-Grade Serous Ovarian Carcinoma1 company · $90M · median $723MUncontested

Newly Diagnosed Glioblastoma pipeline questions

Which biotech companies are developing drugs for Newly Diagnosed Glioblastoma?

Agenus (AGEN, Botensilimab, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Newly Diagnosed Glioblastoma.

How advanced is the Newly Diagnosed Glioblastoma pipeline?

Of the 1 clinical-stage programme in Newly Diagnosed Glioblastoma, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Newly Diagnosed Glioblastoma?

No. AGEN is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Newly Diagnosed Glioblastoma, which is why the indication is classified as uncontested.

When is the next Newly Diagnosed Glioblastoma catalyst?

The next dated catalyst in Newly Diagnosed Glioblastoma is AGEN on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map